November 22, 2002 |
Drug wholesaler Cardinal Health Inc. has started talks about possibly revising its $1.1-billion deal for Syncor International Corp., the Woodland Hills-based nuclear pharmacy services company that is investigating whether its subsidiaries made improper payments to overseas customers. Based on its review so far, Syncor believes it can satisfy conditions of the acquisition, the firms said in a joint statement. Cardinal said it had not concluded whether the merger could be completed.
November 20, 2002 |
Syncor International Corp., which is investigating suspected bribes by its overseas units, said Tuesday that its Taiwan operation made $500,000 in apparently illegal payments to customers in the last five years. Woodland Hills-based Syncor also said a committee of its outside directors turned up "questionable payments and other transactions" in at least six other countries, which it said may have violated the Foreign Corrupt Practices Act and other U.S. laws.
November 14, 2002 |
Seeking more time to investigate possible bribes to foreign officials, nuclear medicine provider Syncor International Corp. said it will request a five-day extension for filing its Sept. 30 quarterly financial results with the Securities and Exchange Commission. In a disclosure that cut its stock price in half last week, Syncor said it hired outside lawyers to investigate payments by its foreign subsidiaries.
June 15, 2002 |
Drug wholesaler Cardinal Health Inc. said it will pay about $870 million in stock to buy Syncor International Corp., the leading provider of pharmacy services that uses radioactive compounds to diagnose and treat ailments. Dublin, Ohio-based Cardinal is buying the business to supplement its 2001 acquisition of Bindley Western, which has a strong franchise in nuclear medicine. The deal's value is based on the 14 million Cardinal shares offered to Syncor holders at $62.
CALIFORNIA | LOCAL
February 27, 2001
Syncor International Corp. in Woodland Hills reported net income of $6.7 million for the fourth quarter that ended Dec. 31, up 46% from $4.6 million for the same quarter the previous year. Revenue rose 27% to $170.6 million from $134.6 million. For the year, net income rose to $29.5 million from $19.2 million. Revenue increased by 21% to $629.4 million from $520 million. Syncor provides high-technology health-care services, including nuclear pharmacy services, medical imaging and radiotherapy.
CALIFORNIA | LOCAL
October 31, 2000
Syncor International Corp., Woodland Hills, reported net income of $6.3 million for the third quarter that ended Sept. 30, compared with $3.2 million for the third quarter last year. Net sales for the quarter rose 18.2% to $155.5 million from $131.5 million. Syncor provides high-technology health-care services including nuclear pharmaceuticals, medical imaging and radiotherapy products.